Low ASL, Lunt M, Mercer LK, et al. Association between ischemic stroke and tumor necrosis factor inhibitor therapy in patients with rheumatoid arthritis. Arthritis Rheumatol 2016; 68: 1337-45.
Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1β induces coronary intimal lesions and vasospastic responses in pigs in vivo: the role of platelet-derived growth factor. J Clin Invest 1996; 97: 769-76.
Buckley LF, Viscusi MM, Tassell B, Van , Abbate A. Interleukin-1 blockade for the treatment of pericarditis. Eur Hear J - Cardiovasc Pharmacother 2018; 4: 46-53.
Van Tassell BW, Canada J, Buckley L, et al. Interleukin-1 blockade in heart failure with preserved ejection fraction: The diastolic heart failure Anakinra response trial 2 (DHART2). Circulation 2017; 136A17709
Klein A, Lin D, Cremer P, et al. Efficacy and safety of rilonacept in recurrent pericarditis: a multicenter phase 2 clinical trial. Circulation 2019; 140A12851
Jin Y, Kang E, Brill G, et al. Comparative cardiovascular safety of abatacept and tumor necrosis factor inhibitors in rheumatoid arthritis patients with and without cardiovascular disease: a population-based cohort study. Ann Rheum Dis 2017; 76: 544.